The inclusion of non-cancer cells decreases HER2 quantification, affecting both the HER2/CEP17 ratio and the average of HER2 copy number per cell, and a high PPV is only achieved with high cancer cellularity (about 85%). This evidence concerns the gene ERBB2 and cancer.